Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88

Benzinga Newsdesk www.benzinga.com Positive 85.3%

Neg 0% Neu 0% Pos 85.3%

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $82 to $88.